Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect

Amgen (Nasdaq:AMGN) announced that the U.S. Food and Drug Administration has approved Neulasta(TM) (pegfilgrastim). Neulasta, administered as a single fixed dose per chemotherapy cycle, for decreasing the incidence of infection, as manifested by febrile neutropenia (fever associated with a severe drop in infection-fighting white blood cells) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

You can reach the story directly by going to

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit to download video, audio, text, graphics, and photos.

If you have any questions about the story, or about, please write to us at


CONTACT: Newstream